<DOC>
	<DOC>NCT01887613</DOC>
	<brief_summary>This study is to investigate the long-term safety and efficacy and the information on the proper use of Regnite® under conditions of daily clinical use.</brief_summary>
	<brief_title>Specified Drug Use-Results Survey of Regnite</brief_title>
	<detailed_description>Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or discontinuation.</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<criteria>Patients with moderate to severe idiopathic restless legs syndrome Patients with a history of hypersensitivity to any ingredients in Regnite or gabapentin Patients with severely impaired renal function (creatinine clearance of less than 30 mL/min)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gabapentin</keyword>
</DOC>